Dalethyne: New hope in wound care!April 9, 2019
Wound and skin care is one of the fast-emerging markets in India for innovative products not only from within the country but also from outside. These areas of care, which saw several new releases in the recent past, has seen the launch of an innovative series from Indonesia, giving new hope for clinicians who treat unsolved chronic and acute burn wounds. These products, developed around the key ingredient—dalethyne and its derivatives, work on the basis of their interaction with the proteins that regulate wound healing in the human body.
According to the innovator, PT Dermazone Pratama Indonesia, dalethyne is a breakthrough in medicinal science. Obtained from a process of fatty acid segregation of extra virgin olive oil, dalethyne has proven with anti-microbial, fungicidal and antiviral qualities with deep-skin penetration.
Kayapan Satya Darshan, the inventor of dalethyne and the founder and chairman of Dermazone Pratama, said that these molecules — synthesized in-house — were docked with various proteins involved in the process of wound healing and the binding energies of the molecules were calculated by the prediction of their Ki values.
“Dalethyne derivatives exhibited sufficient propensity to inhibit the inflammation-causing agents and at the same time allow unhindered execution of the healing process,” he said in an interview with Future Medicine.
“It has proven anti-microbial, fungicidal and antiviral quality with deep skin-penetrable quality. Investigations have revealed that dalethyne reduces inflammation and accelerates wound healing,” he added.
A research paper* published in Science PG in 2018 validates the docking methodology of dalethyne saying: “The binding interactions of the molecules thus calculated were compared with that of the native ligand.”
The report states that, in the normal wound healing process, platelet activation after the wound appearance causes the release of a pro-inflammation cytokine such as TNF-α and IL-1β, which will activate the macrophage.
“The wound will also activate MMP-9 and COX-2. The further release of IL-1β and IL-6 will inhibit the fibroblast production, keratinocyte proliferation and migration; which will delay the epithelization and granulation process. The inhibition of the fibroblast proliferation will cause a decrease of FGF-2 synthesis and therefore will also decrease the TGF- β1 expression regulation. This process will cause a decrease of endothelial cell proliferation and thus will delay the neoangiogenesis and vasculogenesis. At the same time, these phenomena will delay the wound healing process. In the present work, dalethyne derivatives have been predicted to have the ability to suppress the inflammation-causing agent, such as MMP-9 and COX-2. It could also lessen the increased oxidative stress and modulate the expression of the growth factors (FGF-2 and TGF-β1) and inflammation mediator (IL-1β and IL-6), which helps to fix the wound healing process. In the purview of the pharmacology involved in the wound healing process, it was observed that the dalethyne derivatives showed effective interactions with the amino acid residues present in the active site of the proteins, MMP-9 and COX-2. This accounted for the conducive inhibitory effects of these molecules towards the respective receptors,” the report said.
Moreover, the simple structure of the dalethyne derivatives resembling the native ligand attributed to the inability to these molecules to bind with the proteins involved in the process of cell proliferation and re-epithelization. From these observations, it can thus be inferred that the dalethyne derivatives exhibited sufficient propensity to inhibit the inflammation-causing agents and at the same time allow unhindered execution of healing process, the paper cited.
“The results thus provide an insight for the structure of the dalethyne derivatives that would facilitate their activity as wound healing agents. Subsequently, the in-house synthesized molecules can be suitably formulated into a pharmaceutical dosage form that can be efficiently used for the treatment of different types of wounds,” Science PG paper concluded.
“Investigations have revealed that dalethyne successfully reduces inflammation and accelerates wound healing. It has been patented in several countries under my name and this patent is certified as a Novel Innovation Patent in Geneva,” Satya Darshan confirms.
The Jakarta-based company, which has also introduced a range of non-prescription products, including acne wax, face wash and face scrub along with a series of baby care products. It has appointed Delhi-based Alniche Life Sciences, a specialty healthcare company, to handle its marketing and sales of its wound care products. The company is also in talks with Indian companies to market its consumer health products.
* Kayapan Satya Dharshan. Docking Studies for Assessment of Wound Healing Potential of Dalethyne Derivatives: An in-silico Approach. Computational Biology and Bioinformatics. Vol. 6, No. 2, 2018, pp. 36-50. doi: 10.11648/j.cbb.20180602.12